Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
NAMS
#1222
NewAmsterdam Pharma Company N.V. Ordinary Shares
35.460
0
+5.00%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+5.00%
Monatliche Änderung
+9.89%
6 month change
-2.23%
Jahresänderung
-2.23%
Vorheriger Schlusskurs
33.770
0
Open
35.460
0
Bid
Ask
Low
35.460
0
High
35.460
0
Volumen
59
Märkte
Aktien
Gesundheitswesen
NAMS
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
81.56 M
89.27 M
109.82 M
114.98 M
—
Valuation ratios
Enterprise value
913.47 M
726.24 M
2.05 B
3.54 B
9.26 B
Price to earnings ratio
—
-5.56
-10.04
-20.4
-57.13
Price to sales ratio
—
69.68
53.22
184.61
340.87
Price to cash flow ratio
—
-6.95
-15.29
-28.11
-79.59
Price to book ratio
—
3.4
3.2
6.08
8.71
Enterprise value to EBITDA ratio
—
—
-10.6
-14.24
—
Profitability ratios
Return on assets %
—
0.51
0.28
0.26
0.26
Return on equity %
—
0.61
0.32
0.3
0.28
Return on invested capital %
—
2 630.47
1 178.51
1 041.62
—
Gross margin %
—
100
62.28
-3.55
-31.92 K
Operating margin %
—
1 298.56
386.91
1 002.9
224.53 K
EBITDA margin %
—
—
-424.39
-1 105.47
-256.65 K
Net margin %
—
1 255.76
530.25
905.74
256.24 K
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
—
6.95
8.08
7.88
61.51
Inventory turnover
—
—
—
—
—
Asset turnover
—
0.04
0.08
0.03
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
1.72
1.68
1.25
1.25
EBIT per share
—
—
-2.05
-2.1
-2.11
EBITDA per share
—
—
-2.05
-2.1
-2.11
Total debt per share
—
—
—
—
—
Cash per share
—
4.14
8.84
5.37
24.48
Net current asset value per share
—
4.22
9.15
5.71
25.39
Tangible book value per share
—
3.51
8.02
5.77
25.13
Working capital per share
—
3.61
8.02
4.98
23.52
Book value per share
—
3.51
8.03
5.77
25.15
Nachrichten
Cantor Fitzgerald bestätigt "Overweight"-Rating für NewAmsterdam Pharma
Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight
Guggenheim erhöht Kursziel für NewAmsterdam Pharma wegen beschleunigter EU-Markteinführung
Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing
NewAmsterdam Pharma: EPS verfehlt Schätzungen um 0,23 $ - Umsatz schlechter als erwartet
NewAmsterdam Pharma earnings missed by $0.23, revenue fell short of estimates
NewAmsterdam erwartet EMA-Entscheidung zu Cholesterinsenker für zweite Jahreshälfte 2026
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026
NewAmsterdam Pharma: Leerink Partners hebt Kursziel auf 55 US-Dollar an
NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners
Piper Sandler: Diese Biotech-Werte versprechen für 2026 transformatives Wachstum
Piper Sandler highlights commercial biotech names to own in 2026